ABOUT
Kyung-Bo Kim - Ph.D.
Dr. Kim's research interests lie at the interface of chemistry and biology. In particular, his laboratory uses bioactive small molecules including biologically active natural products to explore complex intracellular signaling networks, and to identify and validate novel drug targets.
Selected Publications/Presentations
- Hyosung Lee; Dinesh Puppala; Eun-Young Choi; Hollie Swanson and Kyung-Bo Kim, Targeted Degradation of Aryl Hydrocarbon Receptor via the PROTAC Approach: A Useful Chemical Genetic Tool, ChemBioChem, 8, 2058-2062 (2007)
- Dinesh Puppala; Hyosung Lee; Kyung-Bo Kim and Hollie Swanson, Development of an AHR antagonist using the PROTACs Approach: A Potential Tool for Chemoprevention, Molecular Pharmacology, 73, 1064-1071 (2008)
- Marie Wehenkel, Jin Tae Hong and Kyung Bo Kim, Proteasome Modulators: Essential Chemical Genetic Tools for Understanding Human Diseases, Molecular BioSystems, 4, 280-286 (2008)
- Kyung Bo Kim* and Craig M. Crews, “Chemical Genetics: Exploring the Role of the Proteasome in Cell Biology using Natural Products and other Small Molecule Proteasome Inhibitors”, Journal of Medicinal Chemistry, 51, 2600-2605 (2008)
- Paola Bargagna-Mohan, Adel Hamza, Yang-eon Kim, Yik Khuan (Abby) Ho, Nirit Mor-Vaknin, Nicole Wendschlag, Junjun Liu, Robert M. Evans, David M. Markovitz, Chang-Guo Zhan, Kyung-Bo Kim, Royce Mohan, The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 14, 623-34 (2007)
- Yik Khuan (Abby) Ho, Paola Bargagna-Mohan, Marie Wehenkel, Royce Mohan and Kyung-Bo Kim, LMP2 Subunit-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology, Chemistry & Biology, 14, 419-430 (2007)
- Hyosung Lee; Dinesh Puppala; Eun-Young Choi; Hollie Swanson and Kyung-Bo Kim, Targeted Degradation of Aryl Hydrocarbon Receptor via the PROTAC Approach: A Useful Chemical Genetic Tool, ChemBioChem, in press (2007)
- Abby Ho, Yang-eon Kim, Hyo-Sung Lee, Kedra Cyrus, Sun-Hee Baek and Kyung-Bo Kim Structure-Activity-Relationship studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor machanisms, Bioorg. Med. Chem Lett., 16, 3383-3387 (2006).
- Yasuno Yokota, Paola Bargagna-Mohan, Padma P. Ravindranath, Kyung B. Kim and Royce Mohan, Development of withaferin A analogs as probes of angiogenesis, Bioorg. Med. Chem Lett. 16, 2603-2607 (2006).
- Abby Ho; Kedra Cyrus and Kyung-Bo Kim, Towards Immunoproteasome-Specific Inhibitors: An Improved Synthesis of Dihydroeponemycin, Eur. J. Org. Chem., 22, 4829-4834 (2005).
- Paola Bargagna-Mohan, Sun-Hee Baek, Hyosung Lee, Kyung-Bo Kim and Royce Mohan, Use of PROTACS as Molecular Probes of Angiogenesis, Bioorg. Med. Chem Lett., 15, 2724-7 (2005).
- Kyung Bo Kim, Fabiana N. Fonseca & Craig M. Crews, Development and Characterization of Proteasome Inhibitors, Academic Press, Methods in Enzymology, 399, 585-609 (2005).
- Dong Zhang, Sun-Hee Baek, H. Lee, A. Ho, Y. S. Jeong and K. Kim, Targeted Degradation of Proteins by Small Molecules: A Novel Tool for Functional Proteomics, Combinatorial Chemistry and High Throughput Screening, 7, 691-699 (2004).
- Dong Zhang; Sun-Hee Baek; Abby Ho & Kyungbo Kim, Degradation of Target Protein in Living Cells by Small-Molecule Proteolysis Inducer, Bioorg. Med. Chem Lett., 14, 645-648 (2004).
- Kathy M Sakamoto; Kyung B Kim; Rati Verma; Andy Ransick; Berna Stein; Craig M Crews & Raymond Deshaies, Development of Protacs to Target Cancer-Promoting Proteins for Ubiquitination and Degradation, Molecular & Cellular Proteomics, 2, 1350-1358 (2003).
- K. B. Kim and Crews, C. M. Natural Product and Synthetic Proteasome Inhibitors (Chapter 4), Proteasome Inhibitors in Cancer Therapy (editor, Julian Adams), Apothecom (Boston), 47-63 (2003).
- Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR, Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro, J Clin Invest., 111, 1771-82 (2003).